Walsh discloses conflicts -- five years later

In December, I linkurl:wrote about the fact;http://www.the-scientist.com/blog/display/39136/ that NIH researcher Thomas Walsh, who has faced scrutiny over funding he has received and failed to disclose from drug companies, had apparently failed to disclose conflicts of interest in a paper published in the January 1, 2007 Clinical Infectious Diseases. Now, it seems, journal editors are starting to catch up with stories reporting Walsh's conflicts. In the New England Journal of Medicine that lande

Written byIvan Oransky
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
In December, I linkurl:wrote about the fact;http://www.the-scientist.com/blog/display/39136/ that NIH researcher Thomas Walsh, who has faced scrutiny over funding he has received and failed to disclose from drug companies, had apparently failed to disclose conflicts of interest in a paper published in the January 1, 2007 Clinical Infectious Diseases. Now, it seems, journal editors are starting to catch up with stories reporting Walsh's conflicts. In the New England Journal of Medicine that landed in my mailbox today, there's a correction on page 760. It refers to a study published on January 24, 2002. ''The following line should be included afer the paragraph describing study support (page 233): 'Dr. Walsh reports receiving consulting fees from Pfizer in 2001.'' A note about the correction appears in a link to the linkurl:original paper;http://content.nejm.org/cgi/content/abstract/346/4/225 . I'm of course curious what prompted this disclosure five years after the fact, but I'd also like to know if other belated disclosures will follow. If you see any, please post them here.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies